Interaction pharmacokinetis of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 5, 2004, Pages 452-457

  Briasoulis, Evangelos ^a   Karavasilis, Vasilis ^a   Tzamakou, Eleftheria ^a   Rammou, Dimitra ^a   Soulti, Kali ^b   Piperidou, Christina ^b   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b EurEnvironResInst   (Greece)

Author keywords

Docetaxel; Paclitaxel; Pegylated liposomal doxorubicin; Pharmacokinetics

Indexed keywords

DOCETAXEL; DOXORUBICIN; LIPOSOME; MACROGOL; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; TAXOID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COATING; DRUG INFUSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; DRUG INTERACTION; MIDDLE AGED;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; PACLITAXEL; POLYETHYLENE GLYCOLS; TAXOIDS;

EID: 2142751608     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0750-5     Document Type: Article

References (34)

1. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975
2. Sonpavde G, Ansari R, Walker P, Sciortino DF, Gabrys GT, Murdock A, Gonin R, Einhorn LH (2000) Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol 23:68-70
3. Trope C, Kristensen G, Kisic J, Kaern J (2001) Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer. Eur J Gynaecol Oncol 22:223-227
4. Gehl J, Boesgaard M, Paaske T, Vittrup JB, Dombernowsky P (1996) Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7:687-693
5. Perez EA (2001) Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest 19:155-164
6. Minotti G, Saponiero A, Licata S, Menna P, Calafiore AM, Teodori G, Gianni L (2001) Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 7:1511-1515
7. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699
8. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915
9. Moreira A, Lobato R, Morais J, Silva S, Ribeiro J, Figueira A, Vale D, Sousa C, Araujo F, Fernandes A, Oliveira J, Passos-Coelho JL (2001) Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother Pharmacol 48:333-337
10. Rischin D, Ackland SP, Smith J, Garg MB, Clarke S, Millward MJ, Toner GC, Zalcberg J (2002) Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ann Oncol 13:1810-1818
11. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato DP, Verweij J, Nielsen S (2001) Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870-877
12. Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I, Bruning P, de Valeriola D (2002) EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann Oncol 13:910-918
13. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424-436
14. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029-1033
15. Mavroudis D, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V (2002) Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors. Oncology 62:216-222
16. Tolis C, Briasoulis E, Tzamakou E, Rammou D, Karavasilis V, Piperidou CH, Soulti K, Pavlidis N (2000) Phase I trial and interaction pharmacokinetics of pegylated-liposomal doxorubicin (Caelyx; Doxil) and weekly Taxol (abstract 803). Proceedings Annual Meeting of the American Society of Clinical Oncology
17. Briasoulis E, Rammou D, Tzamakou E, Karavasilis V, Ioannidou A, Soulti K, Pavlidis N (2000) Pegylated-liposomal doxorubicin (Caelyx) plus weekly docetaxel (Taxotere): a phase I and pharmacokinetic study. Ann Oncol 11:134
18. Gabizon AA, Barenholz Y, Bialer M (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10:703-708
19. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992
20. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86:72-78
21. Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436
22. Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, Anagnostopoulos A, Onyenadum A, Papakostas P, Economopoulos T, Christodoulou C, Kosmidis P, Markopoulos C (2002) Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 13:1737-1742
23. Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV (2003) Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol 90:610-618
24. Holmes FA, Rowinsky EK (2001) Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 28:8-14
25. Badary OA, Al Shabanah OA, Al Gharably NM, Elmazar MM (1998) Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice. Anticancer Drugs 9:809-815
26. Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM (1998) Phase I trial of Cremophor EL with bolus doxorubicin. Clin Cancer Res 4:2321-2329
27. Ozpolat B, Lopez-Berestein G, Adamson P, Fu CJ, Williams AH (2003) Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci 6:292-301
28. Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600
29. Jerian S, Keegan P (1999) Cardiotoxicity associated with paclitaxel/trastuzumab combination therapy. J Clin Oncol 17:1647-1648
30. Horton J (2002) Trastuzumab use in breast cancer: clinical issues. Cancer Control 9:499-507
31. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M (1985) Doxorubicin-induced congestive heart failure in adults. Cancer 56:1361-1365
32. Rahman A, More N, Schein PS (1982) Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res 42:1817-1825
33. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454
34. Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC (2001) Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 19:3117-3125